Johnson & Johnson Innovation – JJDC — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases.
BiotechDeep TechHealthtechGaithersburg, US
Samir N. Khleif(Founder & CEO)Ramy Ibrahim(Chief Medical and Strategy Officer)Mikayel Mkrichyan(Senior Vice President of Science and Discovery)Sarah Sharman(Vice President of IP Legal Affairs)
BoardSean Parker(Director)Elena Viboch(Director)
Board seatNancy Ondovik· per SEC Form D · $131.9M raise · filed Aug 2026
Co-investorsCatalio Capital Management, LPHAWKTAILLauder PartnersPrevail Venture CapitalGeneral Catalyst
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.